PPMO's as therapeutic modulators for myotonic dystrophy type 1

Podobne zapisy

• Proteomic evaluation of Pip6a-PMO treatment for myotonic dystrophy type 1
  od: Holland, A, i wsp.
  Wydane: (2018)
• Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice
  od: Klein, AF, i wsp.
  Wydane: (2019)
• Application of antisense conjugates for the treatment of myotonic dystrophy type 1
  od: Stoodley, J, i wsp.
  Wydane: (2023)
• Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy
  od: Liubov V. Gushchina, i wsp.
  Wydane: (2022-12-01)
• Cardiac manifestations in myotonic dystrophy type 1
  od: A. G. Klementieva, i wsp.
  Wydane: (2024-09-01)